Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 17/20 | 0.78 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5212353 | 0.90 | AVPR1A (0.82) | AVPR1ANPC1MAPTHTTRAB9A | |
| SCHEMBL5214851 | 0.89 | AVPR1A (0.81) | AVPR1ANPC1MAPTHTTRAB9A | |
| SCHEMBL5218432 | 0.88 | AVPR1A (1.00) | AVPR1ANPC1MAPTHTTRAB9A | |
| SCHEMBL3105995 | 0.85 | AVPR1A (0.77) | AVPR1ANPC1MAPTHTTRAB9A | |
| SCHEMBL5215427 | 0.84 | AVPR1A (1.00) | AVPR1A | |
| SCHEMBL5212834 | 0.84 | AVPR1A (0.72) | AVPR1A | |
| SCHEMBL5845867 | 0.84 | AVPR1A (0.76) | AVPR1A | |
| SCHEMBL5212432 | 0.84 | AVPR1A (0.76) | AVPR1A | |
| SCHEMBL5216457 | 0.83 | AVPR1A (0.77) | AVPR1AMAPT | |
| SCHEMBL5213181 | 0.83 | AVPR1A (0.77) | AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558598-B1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LTD (GB) | 2007-07-18 | — | — | EP | disclosed |
| EP-1558598-B1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LTD (GB) | 2007-07-18 | — | — | EP | disclosed |
| US-7084145-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1558598-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162278-A1 | Triazole compounds useful in therapy | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885PLD1 1453/4885NPC1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.